Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06218784




Registration number
NCT06218784
Ethics application status
Date submitted
20/12/2023
Date registered
23/01/2024
Date last updated
23/01/2024

Titles & IDs
Public title
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Scientific title
A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers
Secondary ID [1] 0 0
iN1011-N17102
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Post Herpetic Neuralgia 0 0
Pain 0 0
Osteoarthritis 0 0
Neuropathic Pain 0 0
Chronic Pain 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - iN1011-N17 HCl Suspension (Part 1)
Treatment: Drugs - iN1011-N17 HCl Capsule (Part 1)
Treatment: Drugs - Placebo Capsule (Part 1)
Treatment: Drugs - iN1011-N17 HCl Capsule (Part 2)
Treatment: Drugs - iN1011-N17 Mesylate Capsule (Part 2)
Treatment: Drugs - iN1011-N17 HCl Capsule (Part 3)
Treatment: Drugs - iN1011-N17 Mesylate Capsule (Part 3)
Treatment: Drugs - Placebo Capsule (Part 3)

Experimental: iN1011-N17 HCl Suspension (Part 1) - Oral, Preformulation Suspension, b.i.d, Multiple Ascending Dose (Day 1~ Day7)
Part 1:
Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning.

Experimental: iN1011-N17 HCl Capsule (Part 1) - Oral, Nano Suspension Powder Capsule, b.i.d, Multiple Ascending Dose (Day 1~ Day7)
Part 1:
Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning.

Placebo Comparator: Placebo Capsule (Part 1) - Oral, Placebo capsule, b.i.d, Multiple Ascending Dose (Day 1~ Day7)
Part 1:
Participants will receive either iN1011-N17 or placebo in a 3:1 ratio. From Day 1 to Day 6, participants will receive iN1011-N17 or placebo b.i.d in the morning and in the evening, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 7 in the morning.

Experimental: iN1011-N17 HCl Capsule (Part 2) - Oral, Nano Suspension Powder Capsule, Single dose
Part 2:
2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment.

Active Comparator: iN1011-N17 Mesylate Capsule (Part 2) - Oral, AA10 Capsule, Single dose
Part 2:
2-period, randomized, open-label, crossover bioavailability part. Participants will receive a single oral dose of each study treatment (HCl salt and Mesylate salt), one during each of the 2 inpatient periods, in a randomized sequence of administration. There will be a minimum washout period of 5 days between each dose of study treatment.

Experimental: iN1011-N17 HCl Capsule (Part 3) - Oral, Nano Suspension Powder Capsule, b.i.d, Multiple dose (Day 1~ Day7)
Part 3:
2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.
Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning.

Placebo Comparator: iN1011-N17 Mesylate Capsule (Part 3) - Oral, AA10 Capsule, b.i.d, Multiple dose (Day 1~ Day14)
Part 3:
2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.
Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning.

Experimental: Placebo Capsule (Part 3) - Oral, Placebo capsule, b.i.d, Multiple dose (Day 1~ Day14)
Part 3:
2 cohorts with up to 8 healthy volunteers and 8 PHN patients who will be randomized in a ratio of 3:1 to receive iN1011-N17 or placebo.
Each participant in both cohorts will receive oral doses of iN1011-N17/ placebo b.i.d from Day 1 to Day 13, with approximately 12 hours between the 2 daily doses, and receive the last dose on Day 14 in the morning.


Treatment: Drugs: iN1011-N17 HCl Suspension (Part 1)
Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)

Treatment: Drugs: iN1011-N17 HCl Capsule (Part 1)
Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)

Treatment: Drugs: Placebo Capsule (Part 1)
Dose: b.i.d for 7 days

Treatment: Drugs: iN1011-N17 HCl Capsule (Part 2)
Dose: 400 mg QD

Treatment: Drugs: iN1011-N17 Mesylate Capsule (Part 2)
Dose: 400 mg QD

Treatment: Drugs: iN1011-N17 HCl Capsule (Part 3)
Dose: 400 mg b.i.d for 14 days

Treatment: Drugs: iN1011-N17 Mesylate Capsule (Part 3)
Dose: 400 mg b.i.d for 14 days

Treatment: Drugs: Placebo Capsule (Part 3)
Dose: b.i.d for 14 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence, severity, and causality of AEs and serious AEs (SAEs)
Timepoint [1] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Primary outcome [2] 0 0
Incidence of Physical examination abnormalities
Timepoint [2] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Primary outcome [3] 0 0
Incidence of Vital signs abnormalities
Timepoint [3] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Primary outcome [4] 0 0
Incidence of 12-lead ECG abnormalities
Timepoint [4] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Primary outcome [5] 0 0
Incidence of Continous cardiac telemetry abnormalities
Timepoint [5] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Primary outcome [6] 0 0
Incidence of Laboratory tests abnormalities
Timepoint [6] 0 0
Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days
Secondary outcome [1] 0 0
Maximum plasma concentration (Cmax)
Timepoint [1] 0 0
Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1
Secondary outcome [2] 0 0
Time to maximum plasma concentration (Tmax)
Timepoint [2] 0 0
Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1
Secondary outcome [3] 0 0
Terminal half-life (t1/2)
Timepoint [3] 0 0
Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1
Secondary outcome [4] 0 0
Area under the plasma concentration curve (AUC0-12, AUC0-t, AUCinf)
Timepoint [4] 0 0
Part 1: Day 1 and Day 7 Part 2: 0-72 hours post dose Part 3: Day 1 and Day 14
Secondary outcome [5] 0 0
Percentage of AUCinf based on extrapolation (AUC%extrap)
Timepoint [5] 0 0
Part 1: Day 1 and Day 7 Part 2: 0-72 hours post dose Part 3: Day 1 and Day 14
Secondary outcome [6] 0 0
Apparent volume of distribution (Vz/F)
Timepoint [6] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14
Secondary outcome [7] 0 0
Apparent plasma elimination rate constant (?z)
Timepoint [7] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1
Secondary outcome [8] 0 0
Apparent clearance (CL/F)
Timepoint [8] 0 0
Part 1: Day 1 Part 3: Day 1
Secondary outcome [9] 0 0
Fraction excreted unchanged in urine (fe)
Timepoint [9] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14
Secondary outcome [10] 0 0
Amount of drug excreted unchanged in the urine (Ae)
Timepoint [10] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14
Secondary outcome [11] 0 0
Renal clearance (CLR)
Timepoint [11] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14
Secondary outcome [12] 0 0
Mean residence time (MRT)
Timepoint [12] 0 0
Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14
Secondary outcome [13] 0 0
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)
Timepoint [13] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [14] 0 0
Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss)
Timepoint [14] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [15] 0 0
Average steady-state plasma drug concentration during multiple-dose administration (Cav,ss)
Timepoint [15] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [16] 0 0
Time to reach maximum (peak) plasma concentration following drug administration at steady-state (Tmax,ss)
Timepoint [16] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [17] 0 0
Area under the plasma concentration-time curve during a dosage interval (t) (AUCt)
Timepoint [17] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [18] 0 0
Apparent clearance at steady state (CLss/F)
Timepoint [18] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [19] 0 0
Apparent volume of distribution at steady state (Vz,ss/F)
Timepoint [19] 0 0
Part 1: Day 7 Part 3: Day 14
Secondary outcome [20] 0 0
Accumulation ratio of Cmax and AUC (RAcmax or RAAUC)
Timepoint [20] 0 0
Part 1: Day 7 Part 3: Day 14

Eligibility
Key inclusion criteria
Healthy Volunteers

1. Healthy male and female adults, aged 18 to 55 years of age (inclusive) at the time of
consent.

2. Body mass index (BMI = body weight (kg)/[height (m)]2) between 18 kg/m2 and 32 kg/m2
(inclusive) at the time of Screening, and a minimum weight of 45 kg (inclusive).

3. Clinically acceptable pulse rate, RR, and tympanic body temperature (pulse rate
between 45 and 100 beats per minute [bpm]; SBP between 90 and 140 mmHg; DBP between 50
and 90 mmHg; RR between 12 and 22 breaths/min; tympanic body temperature between
35.5°C and 37.7°C at Screening and Day -1). Measurements are to be recorded after a
minimum of 5 minutes of resting in sitting or supine position

For Healthy Volunteers and Post-Herpetic Neuralgia Patients

4. Clinical laboratory values within normal range as specified by the testing laboratory
at Screening and Day -1, unless deemed not clinically significant by the Investigator.

5. All participants (excluding those who are exclusively in same-sex relationships, who
are postmenopausal or have an exclusive partner who is postmenopausal) must agree to
use a highly effective method of contraception throughout the study and for at least
30 days for females or 90 days for males after the last dose of IP. Female
participants must not be breastfeeding, lactating, or pregnant during the study
period.

Female participants are required to be on their chosen contraceptive for at least 7
days before dosing.

Female participants, where their sole, male sexual partner is vasectomized, must
provide a verbal confirmation of azoospermia (90 days following the procedure) which
should be recorded in the source documents by the Investigator.

The minimum timeframe for pre-dose vasectomy for male participants is = 12 weeks,
unless they are the sole sexual partner of a female participant as outlined above.

Male participants who are sexually active must use a condom combined with use of a
highly-effective method of contraception for the female partner (excluding those who
have had a vasectomy or whose partner is postmenopausal). Confirmation of the female
partner's contraceptive information must be provided verbally by the male participant
and should be recorded in the source documents by the Investigator. The postmenopausal
status of the female partner must be confirmed verbally by the male participant and
should be recorded in the source documents by the Investigator.

6. Cognitively capable of understanding the provided information and able to fully comply
with protocol requirements.

7. Written informed consent prior to the commencement of any study procedures.

8. Willing and able to perform the necessary visits to the investigational
site/institution.

9. In good general health at the Investigator's discretion, with no significant medical
history, and with no clinically significant abnormalities on physical examination at
Screening and before the first dose of IP.

Post-Herpetic Neuralgia Patients

10. Male and female adults aged 50 to 75 years of age (inclusive) at the time of consent.

11. Clinically acceptable blood pressure (BP), pulse rate, RR, and tympanic body
temperature (SBP between 90 and 140 mmHg; DBP between 50 and 95 mmHg; pulse rate
between 45 and 100 bpm; RR between 12 and 22 breaths/min; tympanic body temperature
between 35.5°C and 37.7°C) at Screening and Day -1. Measurements are to be recorded
after a minimum of 5 minutes of resting in sitting or supine position.

12. BMI (body weight (kg)/[height (m)]2) between 18 kg/m2 and 40 kg/m2 (inclusive) at the
time of Screening, and a minimum weight of 45 kg (inclusive).

13. A diagnosis of neuropathic pain of PHN is confirmed when the pain for >3 months after
the herpes zoster rash is healed, with the pain area of a continuous area of affected
rash.

14. Douleur Neuropathique 4 (DN4) score =4 at Screening.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
For Healthy Volunteers and Post-Herpetic Neuralgia Patients

1. Presence or history of carcinoma, hepatic, renal, neurological, pulmonary (except for
childhood asthma), endocrine, hematologic, cardiovascular, or genitourinary disease
that, in the opinion of the Investigator, may affect the evaluation of the IP or place
the participant at undue risk (except for conditions that are stable on medications).

2. Presence of any underlying physical or psychiatric condition (except for conditions
that are stable on medications) that, in the opinion of the Investigator, would
undermine participant compliance to protocol requirements.

3. Presence or history of gastrointestinal disease (e.g., peptic ulcer, gastritis,
gastric cramp, gastroesophageal reflex disease, Crohn's disease) or history of
gastrointestinal surgery (except simple appendectomy or herniorrhaphy) that may affect
assessment of safety and PK characteristics of the IP.

4. Presence or history of central nervous system disease that may affect assessment of
safety and PK characteristics of the IP.

5. Presence of herniated disc (inter-vertebral, cervical or both) or history of related
disease that, in the opinion of the Investigator, may affect assessment of safety and
PK characteristics of the IP.

6. History of hypersensitivity to iN1011-N17 or to any of its components.

7. History of allergy or sensitivity to sulfonamides, hay fever, asthma, eczema, food
allergies and/or allergies to other medications. Participants with asymptomatic,
untreated, seasonal allergies at the time of dosing may be considered for inclusion on
a case-by-case basis- PI and Sponsor approval must be obtained prior to randomization.

8. Any abnormal 12-lead ECG findings at Screening and Day -1, deemed by the Investigator
or designee to be clinically significant.

9. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or human
immunodeficiency virus (HIV) at Screening.

10. Positive urine drug screen test (including methamphetamines, opiates, cocaine,
cannabinoids, phencyclidine, benzodiazepines, barbiturates, methadone, tricyclic
antidepressants, and amphetamines) or alcohol breath test at Screening and Day -1.
Repeated tests will be allowed at the discretion of the Investigator for suspected
false positives.

11. Any of the following laboratory abnormalities within 14 days of the first treatment
day:

- Platelet count < 100,000 cells/mm3

- Total neutrophil count < 1500 cells/mm3

- Serum creatinine = 1.5 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) > 3.0 x ULN

- Aspartate aminotransferase (AST) > 3.0 x ULN

- Alkaline phosphatase > 2.0 x ULN

- Bilirubin > 1.5 x ULN

- Temperature = 38°C or any other evidence of an infection

12. Use of any prescription drugs (except the ones mentioned in Section 7.4.1) within 14
days, and over the counter (OTC) medications, herbal remedies (including St John's
Wort), dietary supplements or vitamins within 7 days, or five half-lives of the
product, whichever is longer, before the first dose of IP and for the duration of the
study without prior approval of the Investigator and the MM. This includes analgesics
such as paracetamol and non-steroidal anti-inflammatories (for healthy volunteers
only).

13. The use of any IP or investigational medical device within 30 days prior to Screening,
or five half-lives of the product, whichever is longer.

14. Blood or plasma donation of more than 450 mL within 90 days before the first dose of
IP and for the duration of the study. It is recommended that blood/plasma donations
not be made for at least 30 days after study completion.

15. History of alcoholism, substance or drug abuse-related disorders deemed significant by
the Investigator (or designee) (i.e., participants consuming > 21 units of alcohol per
week for males and > 14 units of alcohol per week for females in the 90 days prior to
dosing will be excluded. One unit of alcohol equals ½ pint [285 mL] of beer or lager,
1 glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits).

16. Use of more than 5 nicotine-based products (including smoking tobacco, smokeless
tobacco, and nicotine patches) per week, within 90 days prior to Screening. Volunteers
must have a negative urine cotinine test at both Screening and Day -1 and refrain from
the use of any nicotine-based products for the duration of the study.

17. Consumption of beverages or foods that contain grapefruit, star fruit, pomelos, or
products containing these fruits, from 7 days, or from the time that is deemed
significant by the Investigator, and products containing caffeine (e.g., coffee, green
tea, black tea, and sodas) from 48 hours before the first dose of IP until discharge
from the study unit (includes the period between Periods 1 and 2 in Part 2).

18. Unwilling to refrain from strenuous exercise from 48 hours prior to admission to the
investigational site/institution and for the duration of the study, where strenuous
exercise is defined as that which requires significant effort, energy, or strength,
such as lifting weights or running.

19. Any other reason that, in the opinion of the Investigator, may affect assessment of
safety, PK, or PD characteristics of the IP.

20. Have previously completed or withdrawn from this study or any other study
investigating iN1011-N17 or have previously received the IP (for healthy volunteers
only).

21. Received an investigational vaccine within 6 months, a live attenuated vaccine within
60 days, or a registered vaccine within 14 days prior to the Day -1 (Baseline visit).

Post-Herpetic Neuralgia Patients

22. PI-NRS score of PHN-associated neuropathic pain over the last 24 hours at
randomization of =9 or at least a daily pain score of =9 during the Washout Period.

23. Previous use of neurolytic block (e.g. chemical neurolytic block using phenol or ethyl
alcohol, or radiofrequency thermocoagulation) or neurosurgical therapy for current
PHN.

24. Other severe pain or the presence of other skin diseases or pain at the site of the
rash at Screening or randomization unrelated to PHN, that may confound the assessment
of PHN.

25. Participants who are unable or unwilling to cease the use of all pain medications,
prescription and otherwise, as of the first day of the study Washout Period and until
after Day 14 of the study. This includes all lamotrigine, carbamazepine,
oxcarbazepine, mexiletine, valproate, lidocaine, lacosamide, amitriptyline,
topiramate, selegiline, rasagiline medications. This excludes the use of paracetamol
provided that a participant is able and willing to utilize a maximum of 4 g of
paracetamol per 24-hour period as of the first day of the study Washout Period and
until after Day 14 of the study. Common and approved medications for PHN patients are
permitted if part of a stable treatment regimen (please refer to Section 7.4.1 for a
list of permitted medications).

26. Participants who are unable or unwilling to cease the use of prohibited medication (in
Section 7.4.1) during the whole study period. Have previously received the IP or any
other investigational drug/device within 30 days or 5 half-lives, whichever is
greater.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
8/02/2024
Actual
Sample size
Target
64
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
iN Therapeutics Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose
Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of
iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia
patients, and to assess the relative bioavailability of Mesylate vs Hydrochloride salt
capsules of iN1011-N17 in Healthy volunteers.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06218784
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Yeseul Shin
Address 0 0
Country 0 0
Phone 0 0
+82313328425
Fax 0 0
Email 0 0
hangsu1208@intherapeutics.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06218784